Navigation Links
Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)
Date:7/16/2014

REDWOOD CITY, Calif., July 16, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept  (Enbrel®), in chronic plaque psoriasis (the RaPsOdy trial).  This announcement follows the recent initiation of a Phase 3 trial of CHS-0214 in rheumatoid arthritis.  The Phase 3 psoriasis trial is a 48-week, randomized, double-blind, active-control, parallel-group, multicenter, global study in subjects with active, chronic plaque psoriasis who are naïve to systemic biologic therapy.  The study will seek to demonstrate biosimilarity between CHS-0214 and Enbrel® in terms of efficacy, safety and immunogenicity.  The primary efficacy endpoint is based on percent improvement in the Psoriasis Area and Severity Index (PASI) at 12 weeks.

"The initiation of the Phase 3 RaPsOdy trial is an important step toward our goal of increasing access to biosimilar etanercept for patients worldwide," said Barbara Finck, M.D., Chief Medical Officer of Coherus.  "It represents a pivotal study in the global clinical development for CHS-0214 and, if positive, will provide support for our marketing applications in Europe, the United States, and a number of other countries."

"Based on our evaluation of the analytical, nonclinical and clinical pharmacokinetic similarity of this molecule, we believe that this molecule has met our rigorous internal criteria for initiating our second Phase 3 trial in 2014," said Denny Lanfear, Coherus Chief Executive Officer.  "In concert with our partner Baxter, we are pleased to advance this product into late-stage development."

"With two late-stage trials now underway in partnership with Coherus, we are advancing our col
'/>"/>

SOURCE Coherus BioSciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
2. Coherus anuncia que CHS-0214 (biosimilar etanercept propuesto) supera punto final primario en decisivo estudio clínico farmacocinético
3. Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
4. Coherus Biosciences Invited to Present at 2014 J.P. Morgan Annual Healthcare Conference
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 A new report by ... type, Form, End user, Application and Geography) - Size, ... Report, Opportunities, Segmentation and Forecast, 2013 - 2020", considers ... on key trends tracked, it is anticipated that the ... by 2020, registering a CAGR of 6.2% from 2014 ...
(Date:10/22/2014)... 2014  With a vision to ensure safety ... Global Pharmaceutical and Biotech manufacturer selects and implements ... solution to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... aggregated by the Xyntek and Antares solution is ...
(Date:10/22/2014)...   BioNano Genomics , the genome mapping ... to purchase an Irys™ System . Among them ... (NCI), NIH Intramural Sequencing Center (NISC) and Genoscope (The ... comprehensive view of a genome was a major ... deliver the scalability or reliability to detect and ...
Breaking Medicine Technology:Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Xyntek and Antares Serialization Solution Protects Pets Too! 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3
... Pfizer Inc. has agreed to provide the ... unique set of electrocardiographic data that will help researchers ... drugs. This is the first time a major ... from one of its drug safety trials, including data ...
... SHELTON, Conn., Jan. 12 Cara Therapeutics, Inc. ... II clinical trial of its long-acting peripheral kappa ... placebo-controlled trial will be conducted in the United ... safety of intravenous CR845 during the post-operative period ...
Cached Medicine Technology:Pfizer Contributes Critical Data to URMC Drug Safety Initiative 2Pfizer Contributes Critical Data to URMC Drug Safety Initiative 3Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain 2
(Date:10/25/2014)... Minneapolis, Minnesota (PRWEB) October 25, 2014 ... a testing firm which verifies IT-accessibility for disabled ... their Access Approved® logo to Mackin Educational ... digital resource management system and to the ... for the "Own Best Medicine" website. ...
(Date:10/25/2014)... 25, 2014 Mesothelioma researchers are reporting ... receive pemetrexed (Alimta), after his combination drug therapy became ... story , just posted on the Surviving Mesothelioma website. ... Medical Center in Japan suggests that “maintenance therapy” with ... who cannot tolerate higher doses of cisplatin. ...
(Date:10/25/2014)... Researchers who discovered antibiotics in farmed and wild ... The use of antibiotics in animals, including ... to the development of antibiotic-resistant bacteria that threaten ... study. Each year in the United States, ... kill about 23,000, according to the Infectious Diseases ...
(Date:10/22/2014)... At a time when the national concussion ... at all levels, the UPMC Sports Medicine Concussion ... where two powerful messages are lost: Concussions can be ... full recoveries every day. , In striving to shift ... research, UPMC and the Concussion Program are unveiling the ...
(Date:10/22/2014)... Springfield, Va. (PRWEB) October 22, 2014 For ... way to make money; it’s an extension of her life’s ... her latest venture as the owner of FirstLight HomeCare, make ... , “It’s important to me that my work makes a ... always harbored an entrepreneurial spirit, so after much research, I ...
Breaking Medicine News(10 mins):Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2
... risk of having fractures, are often routinely prescribed vitamin D ... brought to light the fact that this may not be ... preventing fractures in the elderly people. ,The study had ... All these people were mobile before they had a low ...
... from Sweden had been able to cure people suffering from ... may be a powerful tool for curing allergic reactions. 79 ... to sever allergic rhinitis from grass or pollen were taken ... hay fever for more than two years. Random parallel group ...
... the age of 20yrs may be the protective agent against ... said that breast cells reach their stage of maturity only ... then they are less vulnerable to cancer and earlier the ... cancer. ,The research study had successfully shown that ...
... it may help if they take corticosteroid medication when ... who took corticosteroids whenever they had the symptoms of ... and asthma related decline in lung function as those ... long-term control medication. ,Asthma is considered mild when ...
... scientists have found out that mice with a mutation of ... more and gain weight.// ,The circadian clock is ... organisms. It is this clock that sets the rhythm of ... earlier studies, scientists had been able to find out that ...
... the journal cancer Research, tobacco smoke have been linked with ... Cox 2 is a cellular protein that had been related ... also been related to rise in production of two proteins ... can lead to the production of the chemical Cox 2. ...
Cached Medicine News:
Heine Beta 200 Streak Retinoscope 3.5v w/Twist Lock for Welch-Allyn style handles....
Heine Beta 200 Streak Retinoscope 3.5v...
Video Equipment...
Micro-mini fiber optic light....
Medicine Products: